Compare FLGT & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLGT | VALN |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.3M | 820.0M |
| IPO Year | 2016 | 2021 |
| Metric | FLGT | VALN |
|---|---|---|
| Price | $27.16 | $8.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $28.33 | $15.75 |
| AVG Volume (30 Days) | ★ 272.3K | 20.4K |
| Earning Date | 11-07-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $315,549,000.00 | $211,089,992.00 |
| Revenue This Year | $16.84 | $5.08 |
| Revenue Next Year | $9.74 | $12.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.61 | 13.48 |
| 52 Week Low | $14.57 | $3.62 |
| 52 Week High | $31.04 | $12.25 |
| Indicator | FLGT | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 44.05 |
| Support Level | $26.69 | $8.62 |
| Resistance Level | $31.04 | $9.10 |
| Average True Range (ATR) | 0.77 | 0.29 |
| MACD | -0.46 | 0.02 |
| Stochastic Oscillator | 10.80 | 12.25 |
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.